Alkermes EVP exercises options, sells 9,000 shares

Alkermes plc. executive Craig C. Hopkinson, EVP R&D and Chief Medical Officer, exercised employee stock options for a total of 5,000 ordinary shares at exercise prices of $19.34 and $24.59, and on 2026-08-03 sold 9,000 ordinary shares at $48.58 per share.

Rhea-AI Filing Summary

Alkermes plc. executive Craig C. Hopkinson, EVP R&D and Chief Medical Officer, exercised employee stock options for a total of 5,000 ordinary shares at exercise prices of $19.34 and $24.59, and on 2026-08-03 sold 9,000 ordinary shares at $48.58 per share. These option exercises and the share sale were effected pursuant to a Rule 10b5-1 trading plan adopted on 3/14/2025, and the exercised options were fully vested.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 5 txns

Insider Hopkinson Craig C.

Role EVP R&D, Chief Medical Officer

Sold 9,000 shs ($437K)

Approx. gross sale proceeds $437K

Approx. exercise cost $122K

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (Right to Buy) F1, F3	104	$0.00	$0.00
Exercise	Employee Stock Option (Right to Buy) F1, F3	4,896	$0.00	$0.00
Exercise	Ordinary Shares F1	104	$19.34	$2K
Exercise	Ordinary Shares F1	4,896	$24.59	$120K
Sale	Ordinary Shares F2	9,000	$48.58	$437K

Holdings After Transaction: Employee Stock Option (Right to Buy) — 67,528 contracts (Direct); Ordinary Shares — 69,389 shares (Direct)

Footnotes (3)

1. F1. This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.
2. F2. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.
3. F3. These options are fully vested in accordance with their terms.

Key Figures

Ordinary shares sold: 9,000 shares Sale price: $48.58 per share Options exercised: 5,000 shares +3 more

6 metrics

Ordinary shares sold 9,000 shares Non-derivative sale of ordinary shares on 2026-08-03 at $48.58 per share

Sale price $48.58 per share Price for 9,000 ordinary shares sold on 2026-08-03

Options exercised 5,000 shares Total ordinary shares acquired by exercising employee stock options on 2026-08-03

Exercise price 1 $19.34 per share Conversion price for 104 employee stock options expiring 2031-02-22

Exercise price 2 $24.59 per share Conversion price for 4,896 employee stock options expiring 2032-02-18

Rule 10b5-1 plan adoption date 3/14/2025 Date Craig C. Hopkinson adopted the trading plan governing these transactions

Key Terms

Rule 10b5-1 trading plan, Employee Stock Option (Right to Buy), fully vested

3 terms

Rule 10b5-1 trading plan regulatory

"effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Employee Stock Option (Right to Buy) financial

"security title listed as Employee Stock Option (Right to Buy)"

fully vested financial

"These options are fully vested in accordance with their terms"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transactions did Alkermes (ALKS) executive Craig C. Hopkinson report?

Craig C. Hopkinson reported exercising employee stock options for 5,000 ordinary shares and selling 9,000 ordinary shares on 2026-08-03. The option exercises had strike prices of $19.34 and $24.59, and the sale price was $48.58 per share.

At what prices did Craig C. Hopkinson’s Alkermes (ALKS) option exercises occur?

He exercised employee stock options into ordinary shares at $19.34 and $24.59 per share. These exercises covered 104 options expiring 2031-02-22 and 4,896 options expiring 2032-02-18, resulting in 5,000 ordinary shares that were then part of his reported holdings.

How many Alkermes (ALKS) shares did Craig C. Hopkinson sell and at what price?

Craig C. Hopkinson sold 9,000 ordinary shares at a price of $48.58 per share on 2026-08-03. The transaction is reported as a non-derivative sale of ordinary shares separate from the employee stock option exercises disclosed for the same date.

Were Craig C. Hopkinson’s Alkermes (ALKS) trades under a Rule 10b5-1 plan?

Yes. Both the option exercises and the 9,000-share sale were effected under a Rule 10b5-1 trading plan. The footnotes state the trading plan was adopted by Craig C. Hopkinson on 3/14/2025, covering these reported transactions.

What is the vesting status of the options Craig C. Hopkinson exercised at Alkermes (ALKS)?

The options exercised into ordinary shares were fully vested at the time of exercise. A footnote specifies that these options were fully vested in accordance with their terms, before being exercised for 5,000 ordinary shares on 2026-08-03.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/03/2026 - 07:13 PM Accepted by SEC EDGAR 08/03/2026 - 07:12 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hopkinson Craig C.

(Last) (First) (Middle)

900 WINTER STREET

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Alkermes plc. [ ALKS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP R&D, Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	08/03/2026		M(1)		104	A	$19.34	73,493	D
Ordinary Shares	08/03/2026		M(1)		4,896	A	$24.59	78,389	D
Ordinary Shares	08/03/2026		S(2)		9,000	D	$48.58	69,389	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$19.34	08/03/2026		M(1)			104	(3)	02/22/2031	Ordinary Shares	104	$0	1,252	D
Employee Stock Option (Right to Buy)	$24.59	08/03/2026		M(1)			4,896	(3)	02/18/2032	Ordinary Shares	4,896	$0	66,276	D

Explanation of Responses:

1. This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.

2. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.

3. These options are fully vested in accordance with their terms.

	/s/ Shantale Greenson, attorney-in-fact for Craig C. Hopkinson	08/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)